



Investor presentation

Second quarter and half year of 2026 results

An extract from parent company's, Georgia capital PLC, results file while for the full version they can refer to the following link: [Financial Results | Georgia Capital](#)

FORWARD LOOKING STATEMENTS



This announcement contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Georgia Capital PLC believes that the expectations and opinions reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, certain of which are beyond our control, include, among other things: impact of COVID-19; regional instability; regulatory risk across a wide range of industries; investment risk; liquidity risk; portfolio company strategic and execution risks; currency fluctuations, including depreciation of the Georgian Lari, and macroeconomic risk; and other key factors that could adversely affect our business and financial performance, which are contained elsewhere in this document and in our past and future filings and reports and also the 'Principal Risks and Uncertainties' included in the 1H21 Result Announcement and in Georgia Capital PLC's Annual Report and Accounts 2020. No part of this document constitutes, or shall be taken to constitute, an invitation or inducement to invest in Georgia Capital PLC or any other entity, and must not be relied upon in any way in connection with any investment decision. Georgia Capital PLC and other entities undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Nothing in this document should be construed as a profit forecast.

HEALTHCARE SERVICES BUSINESS OVERVIEW



HEALTHCARE BUSINESS PORTFOLIO

JUNE 2026

35

Hospitals

16

Polyclinics

1


Laboratory

2Q26 AND 1H26 KEY HIGHLIGHTS:

- ✓ EXPANDED SERVICE OFFERINGS ACROSS TBILISI AND THE REGIONS
- ✓ NEW DOCTORS ONBOARDED
- ✓ LAB RETAIL NETWORK FURTHER EXPANDED, REACHING 14 TOTAL RETAIL BRANCHES
- ✓ DELIVERED 16% TOP-LINE AND 20% EBITDA GROWTH Y-O-Y IN 1H26

GEL MILLION

NET REVENUE




WC/Revenue, %


21.5%

17.9%


EBITDA¹



LTM EBITDA AND NET DEBT TO LTM EBITDA¹



EBITDA MARGIN¹



HEALTHCARE SERVICES BUSINESS PERFORMANCE OVERVIEW




HOSPITALS BUSINESS


2Q26 AND 1H26 KEY HIGHLIGHTS:

- ✓ Revenue growth of 18% in 2Q26, supported by expansion of outpatient services, which increased by 21%
- ✓ Operating cash flow reflects seasonality patterns in state cash collections
- ✓ Average length of stay reduced by 0.6 days (1H26 vs 1H25)


OPERATING HIGHLIGHTS² - BED OCCUPANCY RATES (%)




NET REVENUE




EBITDA¹



OPERATING CASH FLOWS¹



HOSPITALS MARKET SHARES | NUMBER OF HOSPITAL BEDS*



*Total number of beds amounts to 16,062

HEALTHCARE SERVICES BUSINESS PERFORMANCE OVERVIEW (CONT'D)




CLINICS & DIAGNOSTICS

2Q26 AND 1H26 KEY HIGHLIGHTS:


- ✓ Number of admissions in polyclinics increased by 6% y-o-y in 2Q26
- ✓ Net revenue grew by 17% y-o-y in 2Q26
- ✓ EBITDA growth amounted to 26% y-o-y in 2Q26
- ✓ Added c.10k registered patients in polyclinics

OPERATING HIGHLIGHTS


NUMBER OF ADMISSIONS (THOUSANDS) - POLYCLINICS



NUMBER OF TESTS PERFORMED (MILLION) - DIAGNOSTICS




NET REVENUE




EBITDA¹

EBITDA margin (excl. IFRS 16)




OPERATING CASH FLOWS¹

EBITDA to cash conversion (excl. IFRS 16)



CLINICS MARKET SHARES | NUMBER OF REGISTERED PATIENTS





HEALTHCARE SERVICES BUSINESS

KEY CONSIDERATIONS

1

EXPANDED MEDICAL INFRASTRUCTURE, STRENGTHENED CLINICAL TEAMS AND ADDED NEW COMPLEX SURGICAL AND OTHER SERVICES WITHIN GHG NETWORK

2

DELIVERED 18% Y-O-Y TOP-LINE GROWTH IN 2Q26

3

EBITDA GROWTH AMOUNTED TO 25%, WITH EBITDA MARGIN IMPROVING BY 1.4 PPTS Y-O-Y IN 2Q26